MARKET

PALI

PALI

Palisade Bio Inc
NASDAQ
2.140
-0.010
-0.47%
After Hours: 2.150 +0.01 +0.46% 19:37 08/14 EDT
OPEN
2.120
PREV CLOSE
2.150
HIGH
2.150
LOW
2.060
VOLUME
1.61M
TURNOVER
--
52 WEEK HIGH
2.855
52 WEEK LOW
0.5300
MARKET CAP
372.94M
P/E (TTM)
-3.3469
1D
5D
1M
3M
1Y
5Y
1D
Maxim Group Sticks to Its Buy Rating for Palisade Bio (PALI)
TipRanks · 2d ago
Palisade Bio (PALI) Receives a New Rating from B. Riley Securities
TipRanks · 2d ago
Palisade Bio (PALI) Receives a Buy from Oppenheimer
TipRanks · 3d ago
Kapoor Reiterates Buy on Palisade Bio, Maintains $7 Price Target as PALI-2108 Advances into Phase 2 IBD Trials
TipRanks · 3d ago
Palisade Bio Q2 Net Loss Expands; Plans Phase 2 ASCENTRA-UC Trial Enrollment In H2 2026; Stock Down
NASDAQ · 3d ago
Palisade Bio reports Q2 EPS (22c), consensus (5c)
TipRanks · 4d ago
Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000K
Benzinga · 4d ago
Palisade Bio GAAP EPS of -$0.05 in-line, revenue of $0.5M
Seeking Alpha · 4d ago
More
About PALI
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and advancing therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company’s lead product candidate, PALI-2108, is being developed as a treatment for patients living with inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Fibrostenotic Crohn’s disease (FSCD). The Company is conducting a Phase I human clinical trial of its lead product candidate, PALI-2108, for the treatment of UC. In UC mouse models, the Company has demonstrated the dose-dependent efficacy of PALI-2108. It utilizes dextran sodium sulfate (DSS)-induced UC mouse models and targets engagement in oxazolone-induced colitis. PALI-2108 targets the key phosphodiesterase-4 (PDE4) in colon tissues and prevents it from breaking down cyclic Adenosine Monophosphate (cAMP) molecules which regulate inflammation in the body.

Webull offers Palisade Bio Inc stock information, including NASDAQ: PALI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PALI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PALI stock methods without spending real money on the virtual paper trading platform.